Valuation: ImmuPharma plc

Market Cap 23.21M 30.67M 26.89M 24.79M 43.52M 2.89B 44.43M 298M 115M 1.43B 115M 113M 4.96B P/E 2024
-2.01x
P/E 2025 -16.8x
Enterprise Value 21.86M 28.89M 25.33M 23.35M 40.99M 2.72B 41.84M 281M 109M 1.35B 108M 106M 4.67B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
94.99%
Yield 2024 *
-
Yield 2025 -
1 day+0.54%
1 week-15.55%
Current month-13.49%
1 month-17.33%
3 months-18.15%
6 months-36.95%
Current year-40.00%
1 week 3.35
Extreme 3.3511
4.98
1 month 3.35
Extreme 3.3511
5.5
Current year 3.35
Extreme 3.3511
11
1 year 1.39
Extreme 1.3861
19.4
3 years 0.82
Extreme 0.822
19.4
5 years 0.82
Extreme 0.822
19.4
10 years 0.82
Extreme 0.822
193.74
Manager TitleAgeSince
Chief Executive Officer 70 2021-07-29
Director of Finance/CFO - 2024-12-02
Chief Tech/Sci/R&D Officer - 2025-08-31
Director TitleAgeSince
Chairman 70 2015-09-29
Director/Board Member 62 2021-07-15
Director/Board Member 60 2021-07-28
Date Insider Type Main position Quantity % Market Cap.
24-04-18Free

Director

3,000,000 0.7204%
24-04-18Free

Director

2,000,000 0.4803%
22-12-21Free

Chief Executive Officer

1,800,000 0.5399%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%-15.55%+47.33%+64.97% 30.51M
-0.48%+7.20%-5.08%+2.45% 46.36B
+2.19%+11.71%+385.81%+632.13% 37.88B
+2.53%+13.93%+20.85%-10.61% 31.12B
+1.65%+3.61%+9.98%+55.42% 30.61B
-4.16%-2.58%+8.74%+15.22% 24.69B
-0.32%+12.96% - - 16.25B
+1.37%+14.53%+71.80%+134.14% 14.85B
+1.00%+10.30%+13.31%+22.84% 13.58B
+3.63%+9.53%+104.07%+107.62% 12.95B
Average +0.79%+6.76%+72.98%+113.80% 22.83B
Weighted average by Cap. +0.71%+8.99%+85.56%+139.09%

Financials

2024 2025
Net sales - -
Net income -2.48M -3.28M -2.88M -2.65M -4.66M -310M -4.75M -31.88M -12.34M -153M -12.32M -12.06M -531M -1.81M -2.39M -2.09M -1.93M -3.39M -225M -3.46M -23.21M -8.98M -111M -8.97M -8.77M -386M
Net Debt -237K -313K -275K -253K -444K -29.53M -453K -3.04M -1.18M -14.6M -1.18M -1.15M -50.62M -1.35M -1.79M -1.57M -1.44M -2.54M -169M -2.59M -17.36M -6.72M -83.32M -6.71M -6.56M -289M
Logo ImmuPharma plc
ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Employees
7
Date Price Change Volume
26-06-26 GBX 3.720 +0.54% 5,317,732
26-06-25 GBX 3.700 -6.80% 4,592,748
26-06-24 GBX 3.970 -3.17% 2,809,341
26-06-23 GBX 4.100 -4.65% 1,628,327
26-06-22 GBX 4.300 -2.38% 1,772,308